<DOC>
	<DOCNO>NCT00371345</DOCNO>
	<brief_summary>This study determine whether investigational drug dasatinib effective treatment woman progressive advanced ER+/PR+ Her2/neu+ breast cancer</brief_summary>
	<brief_title>Study Dasatinib ( BMS-354825 ) Patients With Advanced Estrogen/Progesterone Receptor-positive ( ER+/PR+ ) Her2/Neu-positive ( Her2/Neu+ ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>female , 18 old recurrent , locally advanced , metastatic breast cancer expression ER/PR receptor and/or overexpression Her2/neu paraffinembedded tissue block must available measurable disease prior chemotherapy anthracycline and/or taxane ( neoadjuvant , adjuvant , metastatic setting ) 0 , 1 2 chemotherapy metastatic set adequate organ function Metastatic disease confine bone Symptomatic central nervous system ( CNS ) metastasis Concurrent medical condition may increase risk toxicity Unable take oral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Recurrent , locally-advanced , metastatic breast cancer</keyword>
</DOC>